These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15722690)

  • 21. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value--an Evaluation of Rosuvastatin therapY compared with atorvastatin.
    Fonseca FA; Ruiz A; Cardona-Muñoz EG; Silva JM; Fuenmayor N; Marotti M;
    Curr Med Res Opin; 2005 Aug; 21(8):1307-15. PubMed ID: 16083541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006.
    Tóth PP; Potter D; Ming EE
    J Clin Lipidol; 2012; 6(4):325-30. PubMed ID: 22836069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals.
    Pearson TA; Laurora I; Chu H; Kafonek S
    Arch Intern Med; 2000 Feb; 160(4):459-67. PubMed ID: 10695686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
    Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
    Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals.
    Waters DD; Brotons C; Chiang CW; Ferrières J; Foody J; Jukema JW; Santos RD; Verdejo J; Messig M; McPherson R; Seung KB; Tarasenko L;
    Circulation; 2009 Jul; 120(1):28-34. PubMed ID: 19546386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-density lipoproteins and risk for coronary artery disease.
    Ballantyne CM
    Am J Cardiol; 1998 Nov; 82(9A):3Q-12Q. PubMed ID: 9819098
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The relationship between low-density lipoprotein cholesterol goal attainment and prevention of coronary heart disease--related events.
    Ito MK; Delucca GM; Aldridge MA
    J Cardiovasc Pharmacol Ther; 2001 Apr; 6(2):129-35. PubMed ID: 11509919
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
    Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
    Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
    Maki KC; Galant R; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):59K-64K; discussion 34K-35K. PubMed ID: 16291016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population.
    Fedder DO; Koro CE; L'Italien GJ
    Circulation; 2002 Jan; 105(2):152-6. PubMed ID: 11790693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of computer-generated personalized goals on cholesterol lowering.
    Levetan CS; Dawn KR; Murray JF; Popma JJ; Ratner RE; Robbins DC
    Value Health; 2005; 8(6):639-46. PubMed ID: 16283864
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
    Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
    Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals.
    Shepherd J; Hunninghake DB; Barter P; McKenney JM; Hutchinson HG
    Am J Cardiol; 2003 Mar; 91(5A):11C-17C; discussion 17C-19C. PubMed ID: 12646338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines.
    Brewer HB
    Clin Cardiol; 2003 Apr; 26(4 Suppl 3):III19-24. PubMed ID: 12708635
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry.
    Gitt AK; Juenger C; Jannowitz C; Karmann B; Senges J; Bestehorn K
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16(4):438-44. PubMed ID: 19369876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of high-density lipoprotein cholesterol with periprocedural myocardial injury following elective percutaneous coronary intervention in patients with low-density lipoprotein cholesterol below 70 mg/dL.
    Li XL; Guo YL; Zhu CG; Xu RX; Qing P; Wu NQ; Jiang LX; Xu B; Gao RL; Li JJ
    J Am Heart Assoc; 2015 Jan; 4(1):e001412. PubMed ID: 25572484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.